PMID- 20225909
OWN - NLM
STAT- MEDLINE
DCOM- 20100513
LR  - 20181113
IS  - 1173-2563 (Print)
IS  - 1173-2563 (Linking)
VI  - 30
IP  - 4
DP  - 2010
TI  - Phosphodiesterase type 5 inhibitors for high-altitude pulmonary hypertension: a 
      meta-analysis.
PG  - 259-65
LID - 10.2165/11318360-000000000-00000 [doi]
AB  - BACKGROUND: High-altitude pulmonary hypertension (HAPH) is a public health 
      problem in mountainous areas of the world. Treatment options for this condition 
      are unsatisfactory. Recent interest in use of selective phosphodiesterase type 5 
      (PDE5) inhibitors for pulmonary hypertension has suggested a possible role for 
      these agents in the treatment of HAPH. Preliminary data from several small 
      studies have shown beneficial haemodynamic effects of empirical PDE5 treatment of 
      HAPH but the results of these studies have been challenged. OBJECTIVE: We 
      performed a meta-analysis to explore the potential therapeutic effects of PDE5 
      inhibitors for HAPH. METHODS: Randomized controlled trials were identified to 
      test the effects of PDE5 inhibitors in HAPH by searching PubMed (inception to 
      June 2009). A standardized protocol with predefined criteria was used to extract 
      details on study design, Jadad score, demographic data, interventions and 
      outcomes. The main outcomes assessed were cardiopulmonary parameters. Treatment 
      effects for continuous variables were presented as weighted mean differences with 
      95% confidence intervals. RESULTS: Ten clinical trials were identified and 
      included for the meta-analysis. The weighted mean difference in systolic 
      pulmonary artery pressure post-treatment at rest in PDE5 inhibitor-treated 
      subjects was -7.51 mmHg (95% CI -10.87, -4.16; p < 0.0001) compared with 
      controls, whereas the analysis of systolic blood pressure and heart rate 
      demonstrated that no significant effects were observed in the active treatment 
      group at rest and during exercise. CONCLUSIONS: The available evidence suggests 
      PDE5 inhibitors can attenuate altitude-induced pulmonary hypertension without 
      significantly affecting systemic blood pressure or heart rate.
FAU - Jin, Bo
AU  - Jin B
AD  - Department of Cardiology, Huashan Hospital, Fudan University, Shanghai, China.
FAU - Luo, Xin-Ping
AU  - Luo XP
FAU - Ni, Huan-Chun
AU  - Ni HC
FAU - Shi, Hai-Ming
AU  - Shi HM
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
PL  - New Zealand
TA  - Clin Drug Investig
JT  - Clinical drug investigation
JID - 9504817
RN  - 0 (Phosphodiesterase 5 Inhibitors)
RN  - 0 (Phosphodiesterase Inhibitors)
SB  - IM
MH  - Altitude Sickness/drug therapy
MH  - Blood Pressure/drug effects
MH  - Exercise
MH  - Heart Rate/drug effects
MH  - Humans
MH  - Hypertension, Pulmonary/*drug therapy
MH  - *Phosphodiesterase 5 Inhibitors
MH  - Phosphodiesterase Inhibitors/adverse effects/*therapeutic use
MH  - Pulmonary Artery/physiopathology
MH  - Randomized Controlled Trials as Topic
MH  - Treatment Outcome
EDAT- 2010/03/17 06:00
MHDA- 2010/05/14 06:00
CRDT- 2010/03/16 06:00
PHST- 2010/03/16 06:00 [entrez]
PHST- 2010/03/17 06:00 [pubmed]
PHST- 2010/05/14 06:00 [medline]
AID - 5 [pii]
AID - 10.2165/11318360-000000000-00000 [doi]
PST - ppublish
SO  - Clin Drug Investig. 2010;30(4):259-65. doi: 10.2165/11318360-000000000-00000.